Pharmacological treatment of diabetic patients with cardiovascular complications

Journal of Internal Medicine

Volumn 243, Issue 3, 1998, Pages 181-189

  Sawicki, P T ^a   Berger, M ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Antihypertensive treatment; Cardiovascular disease; Diabetes mellitus; Nephropathy; Oral antidiabetic agents; Smoking

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ORAL ANTIDIABETIC AGENT;

CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; LIPID METABOLISM; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW;

ANTIHYPERTENSIVE AGENTS; CAUSE OF DEATH; CORONARY DISEASE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; INSULIN; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS;

EID: 0031810198     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1998.00279.x     Document Type: Review

References (68)

1. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation 1979; 59: 8-13.
2. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study. Br Med J 1983; 287: 867-70.
3. Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population. Sixteen-year follow-up study. Diabetes 1974; 23: 105-11.
4. Kuususto J, Mykkänen L, Pyörälä K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994; 43: 960-7.
5. International Collaborative Group. Joint discussion: glycemia and CVD. J Chron Dis 1979; 32: 829-37.
6. Sawicki PT, Dähne R, Bender R, Berger M. Prolonged QT interval as a predictor of mortality in diabetic nephropathy. Diabetologia 1996; 39: 77-81.
7. Sawicki PT, Kiwitt S, Bender R, Berger M. The value of QT interval dispersion for identification of total mortality risk in non-insulin-dependent diabetes mellitus. J Intern Med 1998; 243: 49-56.
8. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
9. Borch-Johnsen K, Andersen PK, Deckert T. The effect of proteinuria on relative mortality in Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1985; 28: 590-6.
10. University Group Diabetes Programme. A study of the effects of hypoglycemic agents on vascular complications in patients with adult onset of diabetes. Diabetes 1976; 25: 1129-53.
11. Gerich JE. Oral hypoglycemic agents. N Engl J Med 1989; 321: 1231-45.
12. Leibowitz G, Cerasi E. Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing? Review. Diabetologia 1996; 39: 503-14.
13. Innerfield RJ. Metformin-associated mortality in U.S. studies. N Engl J Med 1996; 334: 1611-12.
14. Stadel BV, Gueriguian J. Metformin-associated mortality in U.S. studies. N Engl J Med 1996; 334: 1613.
15. Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, The Troglitazone Study Group, and Whitcomb RW. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 1997; 46: 433-9.
16. Berger M. To bridge science and patient care in diabetes. Review. Diabetologia 1996; 39: 749-57.
17. Malmberg K, Rydén L, Effendic S, Herlitz J, Nicol P, Waldenström A, Wedel H. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI Study): Effects on mortality at 1 year. J Am Coll Cardiol 1995; 26: 57-65.
18. Malmberg K, Rydén L, Hamsten A, Herlitz J, Waldenström A, Wedel H on behalf of the DIGAMI study group. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. Eur Heart J 1996; 17: 1337-44.
19. Malmberg K. For the DIGAMI Study Group. Prospective randomized study of intensive insulin treatment on long-term survival after acute myocardial infarction in patients with diabetes mellitus. Br Med J 1997; 314: 1512-5.
20. The Hypertension in Diabetes Study Group. Hypertension in Diabetes Study (HDS): II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens 1993; 11: 319-25.
21. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated hypertension. JAMA 1991; 265: 3255-64.
22. Dahlöf B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in Swedish trial in old patients with hypertension. Lancet 1991; 338: 1281-5.
23. Medical Research Council Working Party. MRC trial of treatment of hypertension in older adults. Br Med J 1992; 304: 405-12.
24. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, et al. for the Systolic Hypertension in the Elderly Program Cooperative Research Group. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996; 276: 1886-92.
25. Moser M, Ross H. The treatment of hypertension in diabetic patients. Diabetes Care 1993; 16: 542-7.
26. Lacourcière Y, Nadeau A, Poirier L, Tancède G. Captopril or conventional therapy in hypertensive type 2 diabetics. Three-year analysis. Hypertension 1993; 21: 786-94.
27. Borhani NO, Mercuri M, Borhani PA, Buckalew VM, Canossa-Teriss M, Carr AA, et al. Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS). A randomized controlled trial. JAMA 1996; 276: 785-91.
28. Sawicki PT, Mühlhauser I, Didjurgeit U, Reimann M, Bender R, Berger M. Mortality and morbidity in treated hypertensive Type 2 diabetic patients with micro- or macroproteinuria. Diabetic Med 1995; 12: 893-8.
29. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62.
30. Björck S, Mulec H, Johnsen SA, Norden G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. Br Med J 1992; 304: 339-42.
31. Sawicki PT, Mühlhauser I, Berger M. Captopril, blood pressure, and diabetic nephropathy. JAMA 1994; 272: 1005.
32. Sawicki PT, Berger M. Renal protective effect of enalapril in diabetic nephropathy. Br Med J 1992; 304: 841-2.
33. Bauer JH, Reams GP, Hewett J, Klacho D, Lau A, Messina C, et al. A randomized, double-blind, placebo-controlled trial to evaluate the effect of enalapril in patients with clinical diabetic nephropathy. Am J Kidney Dis 1992; 20: 443-57.
34. Elving LD, Wetzels JMF, van Lier HJJ, de Nobel E, Berden JHM. Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Diabetologia 1994; 37: 604-9.
35. Weidmann P, Boehlen M, de Courten M. Effects of different antihypertensive drugs on human proteinuria. Nephrol Dial Transplant 1993; 8: 582-4.
36. Parving HH, Rossing P. The use of antihypertensive agents in prevention and treatment of diabetic nephropathy. Curr Opin Nephrol Hypertens 1994; 3: 292-300.
37. Sawicki PT, Berger M. Measuring progression of diabetic nephropathy. Review. Eur J Clin Invest 1994; 24: 651-5.
38. Rossing P, Tarnow L, Boelskifte S, Jensen BR, Nielsen FS, Parving HH. Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. Diabetes 1997; 46: 481-7.
39. Sawicki PT. Stabilisation of glomerular filtration rate over two years in patients with diabetic nephropathy under intensified therapy regimens. Nephrol Dial Transplant 1997; 12: 1890-99.
40. Sawicki PT, Mühlhauser I, Didjurgeit U, Baumgartner A, Bender R, Berger M. Intensified antihypertensive therapy is associated with improved survival in type 1 diabetic patients with nephropathy. J Hypertens 1995; 13: 933-8.
41. Parving H-H, Hommel E. Prognosis in diabetic nephropathy. Br Med J 1989; 99: 230-3.
42. Mathiesen ER, Borch-Johnsen K, Jensen DV, Deckert T. Improved survival in patients with diabetic nephropathy. Diabetologia 1989; 32: 884-6.
43. Maschio G, Alberti D, Janin G, Locatelli F, Mann JE, Motolese M, et al. and the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. The effect of the angiotensin-converting-enzyme inhibitor benazapril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939-45.
44. Rossing P, Hougaard P, Borch-Johnsen K, Parving HH. Predictors of mortality in insulin dependent diabetes: 10 year observational study. Br Med J 1996; 313: 779-84.
45. Jensen T, Borch-Johnsen K, Kofoed-Enevoldsen A, Deckert T. Coronary heart disease in young Type 1 (insulin-dependent) diabetic patients with and without nephropathy: incidence and risk factors. Diabetologia 1987; 30: 144-8.
46. Sawicki PT. Lisinopril and albumin excretion in diabetes, Lancet 1997; 350: 662-63 (letter).
47. Kjekshus J, Gilpin E, Cali G, Blackey AR, Henning H, Ross J Jr. Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J 1990; 11: 43-50.
48. Jonas M, Reicher-Reiss H, Boyko V, Shotan A, Mandelzweig L, Goldbourt U, Behar S, for the Bezafibrate Infarction Prevention (BIP) Study Group. Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Am J Cardiol 1996; 771: 1273-1277.
49. The Danish Study Group on Verapamil in Myocardial Infarction. The Danish studies on verapamil in acute myocardial infarction. Br J Clin Pharmacol 1986; 21: 197S-204S.
50. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW, on behalf of the INTACT Group. Retardation of angiographic progression of coronary artery disease by nifedipine: results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). Lancet 1990; 335: 1109-13.
51. Goldbourt U, Behar S, Reicher-Reis H, Zion M, Mandelzweig L, Kaplinsky E, for the SPRINT Study Group. Early administration of nifedipine in suspected acute myocardial infarction: the Secondary Prevention of Reinfarction Israel Nifedipine Trial 2 Study. Arch Intern Med 1993; 153: 345-53.
52. Moy CS, LaPorte RE, Dorman JS, Songer TJ, Orchard TJ, Kuller LH, et al. Insulin-dependent diabetes mellitus mortality. The risk of cigarette smoking. Circulation 1990; 82: 37-43.
53. Rosengren A, Welin L, Tsipogianni A, Wilhelmsen L. Impact of cardiovascular risk factors on coronary heart disease and mortality among middle aged diabetic men: a general population study. Br Med J 1989; 299: 1127-31.
54. Morrish NJ, Stevens LK, Head J, Fuller JH, Jarrett RJ, Keen H. A prospective study of mortality among middle-aged diabetic patients (the London cohort of the WHO multinational study of vascular disease in diabetics) II: associated risk factors. Diabetologia 1990; 33: 542-8.
55. Ford E, DeStefano F. Risk factors for mortality from all causes and from coronary heart disease among persons with diabetes. Findings from the National Health and Nutrition Examination Survey I. Epidemiological follow-up study. Am J Epidemiol 1991; 133: 1220-30.
56. Sawicki PT, Mühlhauser I, Bender R, Pethke W, Heinemann L, Berger M. Effects of smoking on blood pressure and proteinuria in patients with diabetic nephropathy. J Intern Med 1996; 239: 345-52.
57. Sawicki PT, Didjurgeit U, Mühlhauser I, Bender R, Heinemann L, Berger M. Smoking is associated with progression of diabetic nephropathy. Diabetes Care 1994; 17: 126-31.
58. Stegmayr B, Lithner F. Tobacco and end stage diabetic nephropathy. Br Med J. 1987; 295: 581-2.
59. Mühlhauser I. Smoking and diabetes. Diabetic Med 1990; 7: 10-15.
60. Sawicki PT, Didjurgeit U, Mühlhauser I, Berger M. Behaviour therapy versus doctor's anti-smoking advise in diabetic patients. J Intern Med 1993; 234: 407-9.
61. Henningfield JE. Nicotine medications for smoking cessation. N Engl J Med 1995; 333: 1196-1203.
62. Koskinen P, Mänttäri M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992; 15: 820-5.
63. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. for The Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
64. Pyörälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G, The Scandinavian Simvastatin Survival Study (4S) Group. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 1997; 20: 614-20.
65. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trial of antiplatelet therapy,I: prevention of death, myocardial infarction, and stroke by prolonged antipletelet therapy in various categories of patients Br Med J 1994; 308: 81-106.
66. Colwell JA, Bingham SF, Abreira C, Anderson JW, Comstock JP, Kwaan HC, and the Cooperative Study Group. Veterans Administration cooperative study on antiplatelet agents in atherosclerotic vascular diseases rates. Diabetes Care 1986; 9: 140-8.
67. Early Treatment of Retinopathy Study Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 14. JAMA 1992; 268: 1292-300.
68. Yudkin J. Which diabetic patients should be taking aspirin? Br Med J 1995; 311: 641-2.